Valerija Bralic Lang

Valerija Bralic Lang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Primary Care Diabetes
Verified
Journal Article
Closed access
VLValerija Bralic Lang
Valerija Bralic Lang
MBMaja Baretić
Maja Baretić

17 April 2024 in Lijecnicki Vjesnik
Verified
Journal Article
Open access
PDF file
VLValerija Bralic Lang
Valerija Bralic Lang
Introduction and objective: Deprescribing refers to a process of medication withdrawal, supervised by a health care professional, with the goal of managing polypharmacy and improving outcomes. The aim of this paper is to highlight the key points on who may benefit from and how to deliver deprescription. Methods: The scientific literature available on PubMed in English for recent 10 years related to deprescription was reviewed. Results: Medication-related problems are extremely common in older adults and include adverse drug effects, ineffectiveness, use of medications with no indication, excessive or inadequate dosing, use of potentially inappropriate medications, and nonadherence. Patient characteristics which are good targets for deprescribing efforts include polypharmacy, multimorbidity, renal impairment, transitions of care, medication nonadherence, limited life expectancy, older age, frailty, and dementia. Commonly overused and high-risk medications sedative-hypnotics, strongly anticholinergic medications, long-acting sulfonylureas, and chronic use of proton pump inhibitors and nonsteroidal anti-inflammatory drugs in the absence of compelling indications are good targets for deprescribing. Deprescribing is best accomplished in a stepwise approach which includes engaging the patient and gathering information, identifying, and deciding on medications to deprescribe, and implementing a deprescribing plan with monitoring and follow-up. Shared decision-making is essential and should include alignment of patient goals and preferences. Effective communication is needed not only between patients and clinicians but also between health care professionals, family, and care givers. Conclusion: Common goals for deprescribing include reducing overall medication burden, reducing the risk of specific geriatric syndromes such as falls and cognitive impairment, and improving global health outcomes such as hospitalization and death.


18 July 2025 in Medicina
Verified
Journal Article
Open access
PDF file
IBIvan Budimir Bekan
Ivan Budimir Bekan
DŠDino Šisl
Dino Šisl
ASAlan Sucur
Alan Sucur
Ana BainrauchAna Bainrauch
Ana Bainrauch
VLValerija Bralic Lang
Valerija Bralic Lang
TKTomislav Kelava
Tomislav Kelava
Background and Objectives: Patients with GG rs738409 patatin-like phospholipase domain-containing protein 3 (PNPLA3) genotype (148M variant) have greater risk to develop end-stage liver disease and its associated clinical complications, including hepatocellular carcinoma (HCC). We aimed to analyze the association between the PNPLA3 genotype and augmented inflammatory response in transplant candidates with end-stage alcoholic liver disease (ALD). Materials and Methods: Concentrations of 13 cytokines were measured in 106 end-stage ALD patients without HCC (40 with CC, 40 with CG, and 26 with GG genotype), 35 end-stage ALD patients with HCC, and 19 control patients by cytometric bead array. Results: We found significantly higher concentrations of IL-1, IFN-α, IFN-γ, TNF-α, IL-6, CXCL8, IL-10, IL-12, IL-32, and IL-33 in patients with ALD compared to controls, while the concentration of CCL2 was significantly lower. No differences were observed in the concentration of IL-17 and IL-18. ALD patients with and without HCC had similar cytokine concentrations (p > 0.05 for all comparisons). End-stage ALD patients without HCC of the GG genotype had significantly higher CCL2 concentrations (212.6 [135.9–264.9] pg/mL) compared to end-stage ALD patients without HCC carrying the CC/CG genotypes (141.3 [104.1–201.6] pg/mL, p = 0.002, Mann–Whitney). No significant differences across the genotypes were found for the remaining measured cytokines (p > 0.05). GG carriers also had significantly higher levels of AST and ALT, and lower platelet counts. Conclusions: End-stage ALD patients without HCC who carry the PNPLA3 GG genotype have relatively higher CCL2 levels compared to those with the CC or CG genotypes. Relatively elevated CCL2 concentrations in GG patients might contribute to their increased risk of developing clinical complications compared to CC/CG patients.